NCT06251102

Real-world Ruxolitinib Experience in PV

Real-world Ruxolitinib Experience in Polycythemia Vera: REVIEW Study

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 153 (estimated)
• Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

This is a multicentric, observational, retro-prospective study in adult PV patients - resistant or intolerant to hydroxyurea - who are going to receive or have already initiated treatment with ruxolitinib according to the approved local label. Enrolment will last 9 months after the first enrolled patient. Patients will be observed for a minimum of 3 months, in order to evaluate the primary endpoint for all patients.

Detailed description

This is a multicentric, observational, retro-prospective study in adult population who have been diagnosed with polycythemia vera according to the 2022 (WHO or ICC) criteria, who are resistant or intolerant to hydroxyurea and who are going to be prescribed or have already initiated treatment with ruxolitinib according to the approved local label. Patients who started treatment with ruxolitinib - according to clinical practice - will be enrolled. Enrolment will last 9 months after the first enrolled patient. Patients will be observed for a minimum of 3 months, in order to evaluate the primary endpoint for all patients.

Conditions

• Polycythemia Vera

Timeline

• Start date: 2024-07-01
• Primary completion: 2025-07-01
• Completion: 2025-07-01
• First posted: 2024-02-09
• Last updated: 2024-05-09